| Identification | Back Directory | [Name]
CY-09 | [CAS]
1073612-91-5 | [Synonyms]
CY-09
CS-2756
CY 09;CY09
CY09;CY 09;CY-09
4-[[4-Oxo-2-thioxo-3-[3-(trifluoromethyl)benzyl]thiazolidin-5-ylidene]methyl]benzoic Acid
(E)-4-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic acid
4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]benzoic acid
Benzoic acid, 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]- | [Molecular Formula]
C19H12F3NO3S2 | [MDL Number]
MFCD31619349 | [MOL File]
1073612-91-5.mol | [Molecular Weight]
423.43 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:65.0(Max Conc. mg/mL);152.61(Max Conc. mM) | [form ]
A crystalline solid | [color ]
Light yellow to yellow | [InChI]
1S/C19H12F3NO3S2/c20-19(21,22)14-3-1-2-12(8-14)10-23-16(24)15(28-18(23)27)9-11-4-6-13(7-5-11)17(25)26/h1-9H,10H2,(H,25,26)/b15-9+ | [InChIKey]
DJTINRHPPGAPLD-OQLLNIDSSA-N | [SMILES]
OC(C(C=C1)=CC=C1/C=C(SC2=S)\C(N2CC3=CC=CC(C(F)(F)F)=C3)=O)=O |
| Hazard Information | Back Directory | [Uses]
CY-09, exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). CY-09 is an NLRP3 inhibitor. | [Biological Activity]
CY-09 is an NLRP3 inflammasone inhibitor. CY-09 binds directly to the ATP-binding motif of NLRP3 NACHT domain and inhibits its ATPase activityblocking NLRP3 inflammasome assembly and activation. In mouse models CY-09 showed therapeutic effects in type 2 diabetes and cryopyrin-associated auto-inflammatory syndrome (CAPS)which is caused by gain-of-function mutations of NLRP3. | [in vivo]
CY-09 treatment in vivo efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation in vivo. CY-09 treatment also increases the survival of NLRP3 mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of high-fat diet (HFD)-treated mice is also suppressed by CY-09[1]. | [IC 50]
NLRP3 | [storage]
Store at +4°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|